ArticleScience (New York, N.Y.)2022
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets.
Open access · greenAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 195 papers.
0numbers the graph read from it
0cells of the map it votes in
195citing papers in PubMed
36.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
195 citing papers in PubMed, 256 citations in OpenAlex.
- Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer.Signal transduction and targeted therapy · 2026Trial
- Article
- ERG Orchestrates a Dedifferentiation-Senescence-Inflammation Triad in Prostate Cancer.Molecular cancer research : MCR · 2026Article
- Commensal Nakaseomyces glabratus migrates into prostate tumors to accelerate cancer progression.Nature cancer · 2026Article
- Androgen receptor drives divergent chromatin accessibility programs in benign and malignant prostate epithelial cells.Nucleic acids research · 2026Article
- ATP-dependent chromatin remodelers in prostate cancer progression and therapeutic resistance.Endocrinology · 2026Review
- Article
- Increasing Cancer Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival.bioRxiv : the preprint server for biology · 2026Article
- SPEN inactivation drives resistance to androgen receptor pathway inhibitors in metastatic prostate cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Nicotinic Acid Restriction Enhances the Therapeutic Benefit of NAMPT Inhibition in Small-Cell Lung Cancer Models.Cancer science · 2026Article
- Glutamate Ionotropic Kainate Receptors as Therapeutic Targets in Enzalutamide-Resistant and Neuroendocrine Prostate Cancer.International journal of molecular sciences · 2026Article
- Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in a Hippo-dependent cancer model.Nature communications · 2026Article
- Mapping prostate cancer pathobiology: A review of genetically engineered mouse models (GEMMs).Gene · 2026Review
- Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.Nature communications · 2026Article
- Therapeutic targeting of the eIF4E cap-binding domain reveals control of lineage fate in prostate cancer.The Journal of clinical investigation · 2026Article
- Beyond PSMA: theranostic cell surface targets in metastatic prostate cancer.Prostate cancer and prostatic diseases · 2026Review
- Review
- Ferroptosis vulnerability of enzalutamide resistant prostate cancer conferred by ACSL4 overexpression and GPX4 antagonism.Cell death & disease · 2026Article
- 3D genome architecture and epigenetic regulation of lineage identity in advanced prostate cancer.Endocrinology · 2026Review
- DDX5 (p68) and UbE2T as emerging superior cancer therapeutic targets: dual molecular glue target degradation by FL118 for conquering difficult-to-treat cancers.Journal of experimental & clinical cancer research : CR · 2026Review
135 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on byUro-Science.2023
Authors and funding
32 authors at 2 institutions in 2 countries.
Fanying Tang *Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0003-1887-5764
Duo Xu *Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0002-2445-5662
Shangqian Wang *Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0001-7470-1246
Chen Khuan Wong *Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0001-9811-3334
Alexander Martinez-FundichelySandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0002-7660-5511
Cindy J LeeHuman Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Sandra CohenSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.
Jane ParkCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Corinne E HillCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0001-7567-0066
Kenneth EngEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0002-3404-3610
Rohan BarejaEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA.
Teng HanHuman Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Eric Minwei LiuSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0002-3594-6678
Ann PalladinoSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.
Wei DiHuman Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-6398-986X
Dong GaoHuman Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0003-1821-2741
Wassim AbidaDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-9006-7043
Shaham BegEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA.
Loredana PucaSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0002-0895-1519
Maximiliano MenesesAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-4093-3070
Elisa de StanchinaAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-3873-315X
Michael F BergerDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0003-3882-5000
Anuradha GopalanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Lukas E DowSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.
Juan Miguel MosqueraSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0003-4666-6476
Himisha BeltranEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0003-3259-2226
Cora N SternbergSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0003-3938-2627
Ping ChiHuman Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-0159-5531
Howard I ScherDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-6791-9324
Andrea SbonerInstitute for Computational Biomedicine, Weill Cornell Medical College, New York, NY 10021, USA.ORCID 0000-0001-6915-3070
Yu ChenHuman Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-0171-3884
Ekta KhuranaSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0002-4351-7566
Memorial Sloan Kettering Cancer Center · USCornell University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MSPORE in Bladder CancerP50CA221745 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BAJORIN, DEAN F. · 2018 to 2024
$11.8MWeill Cornell Medicine (WCM) SPORE in Prostate CancerP50CA211024 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LODA, MASSIMO · 2017 to 2021
$10.9MThe MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity CenterU54CA224079 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2017 to 2021
$6.8MPatient-Derived Models of Prostate Cancer for Personalized MedicineU01CA224044 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHEN, YU, FUTREAL, PHILLIP ANDREW · 2019 to 2023
$5.1MPredicting the functional impact of non-coding mutations using patient-specific gene regulatory networksR01CA218668 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI EKTA KHURANA, Neville Sanjana · 2018 to 2026
$4.7MRole of ETS factors in specifying prostate luminal cell identity and androgen receptor dependenceR01CA193837 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2015 to 2025
$4.7MMolecular mechanisms underlying lineage plasticity in prostate cancerR37CA241486 · NCI · DANA-FARBER CANCER INST · PI Himisha Beltran · 2020 to 2026
$4.1MUnderstanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST)U01CA252048 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHI, PING · 2021 to 2025
$3.1MAn integrative approach to target lineage-specific oncogenic transcription factorDP2CA174499 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHI, PING · 2012 to 2012
$2.6MEpigenetic mechanisms of transcriptional activation of a novel oncogenic ALK variant in cancerR01CA228216 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHI, PING · 2018 to 2022
$2.5MUnderstanding the role of an aberrant hepatic nuclear transcription circuit in prostate cancer tumorigenesis and castration resistanceR01CA208100 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHEN, YU · 2017 to 2021
$2.5MNCI NIH HHS DP2 CA174499NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA211024NCI NIH HHS P50 CA221745NCI NIH HHS R01 CA193837NCI NIH HHS R01 CA208100NCI NIH HHS R01 CA218668NCI NIH HHS R01 CA228216NCI NIH HHS R37 CA241486NCI NIH HHS U01 CA224044NCI NIH HHS U01 CA252048NCI NIH HHS U54 CA224079
Abstract
In castration-resistant prostate cancer (CRPC), the loss of androgen receptor (AR) dependence leads to clinically aggressive tumors with few therapeutic options. We used ATAC-seq (assay for transposase-accessible chromatin sequencing), RNA-seq, and DNA sequencing to investigate 22 organoids, six patient-derived xenografts, and 12 cell lines. We identified the well-characterized AR-dependent and neuroendocrine subtypes, as well as two AR-negative/low groups: a Wnt-dependent subtype, and a stem cell-like (SCL) subtype driven by activator protein-1 (AP-1) transcription factors. We used transcriptomic signatures to classify 366 patients, which showed that SCL is the second most common subtype of CRPC after AR-dependent. Our data suggest that AP-1 interacts with the YAP/TAZ and TEAD proteins to maintain subtype-specific chromatin accessibility and transcriptomic landscapes in this group. Together, this molecular classification reveals drug targets and can potentially guide therapeutic decisions.
Indexed as
ChromatinMolecular Targeted TherapyProstatic Neoplasms, Castration-ResistantCell Line, TumorGene Expression ProfilingHumansMaleNeoplastic Stem CellsOrganoidsReceptors, AndrogenTranscription Factor AP-1ChromatinReceptors, AndrogenTranscription Factor AP-1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.